Antiviral therapy of COVID-19

  • Slobodan M Janković Univerzitet u Kragujevcu, Fakultet medicinskih nauka
DOI: https://doi.org/10.5937/scriptamed51-28336

Sažetak


Пандемија COVID 19 је захтевала брзи одговор на потребе критично оболелих пацијената, а једно од решења била је пренамена лекова широког спектра антивирусног деловања за лечење SARS-CоV-2 инфекције. најпре се почело са ваниндикационом упоптребом у једном или у неколико случајева, да би се наставило након првих обећавајућих резултата са рандомизираним клиничким испитивањима. Постоји неколико лекова који се тренутно тестирају у текућим клиничким испитивањима: антималарици хидроксихлорокин и хлорокин, инхибитори HIV протеазе лопинавир / ритонавир, антивирусни лекови широког спектра умифеновир (лек против грипа) и фавипиравир, антипаразитарни лек ивермектин и нуклеозидни аналог ремдесивир. Међутим, до данас је завршено и објављено само неколико испитивања, што спречава коначне закључке о ефикасности и сигурности ових лекова. Док се не заврше главна клиничка испитивања, лекари који одлуче да користе ове лекове ван индикационог подручја би требало да правилно информишу своје пацијенте о свим потенцијалним ризицима и користима и да траже њихов пристанак пре примене лекова.

Biografija autora

Slobodan M Janković, Univerzitet u Kragujevcu, Fakultet medicinskih nauka
Redovni profesor Farmakologije i toksikologije i Klinicke farmacije

Reference

1. Andrade KRC de, Carvalho VK da S, Farinasso CM, Lima AA de, Silva RB, Wachira VK, et al. Pharmacological therapies for patients with human coronavirus infections: a rapid systematic review. Cienc Saude Coletiva. 2020 Sep;25(9):3517–54.
2. McKee DL, Sternberg A, Stange U, Laufer S, Naujokat C. Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacol Res. 2020 Jul 1;157:104859.
3. Hernandez AV, Roman YM, Pasupuleti V, Barboza JJ, White CM. Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review. Ann Intern Med. 2020 18;173(4):287–96.
4. Lima WG, Brito JCM, Overhage J, Nizer WS da C. The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review. Arch Virol. 2020 Aug;165(8):1729–37.
5. Liu W, Zhou P, Chen K, Ye Z, Liu F, Li X, et al. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis. CMAJ. 2020 Jul 6;192(27):E734–44.
6. Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic? J Virus Erad. 2020 Apr 30;6(2):45–51.
7. Nasir M, Perveen RA, Saha SK, Talha KA, Selina F, Islam MA. Systematic Review on Repurposing Use of Favipiravir Against SARS-CoV-2. Mymensingh Med J MMJ. 2020 Jul;29(3):747–54.
8. Verdugo-Paiva F, Izcovich A, Ragusa M, Rada G. Lopinavir-ritonavir for COVID-19: A living systematic review. Medwave. 2020 Jul 15;20(6):e7967.
9. Vargas M, Servillo G, Einav S. Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review. Eur Rev Med Pharmacol Sci. 2020 Aug;24(16):8592–605.
10. Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot (Tokyo). 2020;73(9):593–602.
11. Chaccour C, Ruiz-Castillo P, Richardson M-A, Moncunill G, Casellas A, Carmona-Torre F, et al. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial. Trials. 2020 Jun 8;21(1):498.
12. Frediansyah A, Nainu F, Dhama K, Mudatsir M, Harapan H. Remdesivir and its antiviral activity against COVID-19: A systematic review. Clin Epidemiol Glob Health. 2020 Aug 7;
13. Cox S. To dispense or not to dispense: Lessons to be learnt from ethical challenges faced by pharmacists in the COVID-19 pandemic. Dev World Bioeth. 2020 Aug 25;
Objavljeno
2020/09/30
Broj časopisa
Vol. 51 Br. 3 (2020): Q3
Rubrika
Uvodnik
Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).